NIH's All of Us Program Releases Major Dataset Expansion Linking 535,000 Genomes with EHR Data to Advance Precision Medicine

The National Institutes of Health查看公司主页 has released a major expansion of its All of Us Research Program (搜索)搜索该词条 dataset, providing researchers with access to genomic, clinical, behavioral, environmental, and wearable-device data from a large and diverse US population. The updated resource includes data contributed by more than 747,000 participants, enabling the linkage of nearly 482,000 electronic health records (EHRs) connected to 535,000 whole genome sequences.

The release marks a significant step toward the program's goal of enrolling at least 1 million participants and following their health over time. It also addresses a persistent data gap: despite 98% of participants agreeing to share their electronic health records for research, more than 300,000 previously had no EHR data in the database.

Bridging Genomics and Real-World Clinical Data

The expanded dataset contains more than 1.3 billion genetic variants, giving researchers an opportunity to study both common and rare genetic differences alongside diagnoses, laboratory findings, medication use, socioeconomic factors, and environmental exposures. All data are organized within a secure, cloud-based research environment known as the All of Us Researcher Workbench.

This integrated approach reflects the understanding that genetics alone often cannot explain why a disease develops, how quickly it progresses, or why patients respond differently to the same treatment. By linking genomic findings with clinical and real-world data, researchers may better evaluate the combined effects of biology, behavior, environment, and health care access.

An earlier analysis of 245,388 whole-genome sequences from All of Us identified more than 1 billion genetic variants, including over 275 million variants that had not previously been reported. Researchers also demonstrated that linking genomic results with longitudinal EHR data could support the evaluation of genetic associations across multiple diseases and ancestry groups.

Unprecedented Diversity in Genomic Research

A central feature of All of Us is its emphasis on populations that have historically been underrepresented in biomedical research. According to the NIH, more than 86% of program participants represent communities—including racial and ethnic minority groups, rural populations, individuals with disabilities, and people facing socioeconomic barriers—that have traditionally been overlooked in health research.

The lack of diversity in earlier genomic studies has limited the generalizability of some genetic associations and risk-prediction tools. Many large genomic datasets have disproportionately represented individuals of European ancestry, creating uncertainty about whether findings apply consistently across populations. Expanding the number and diversity of available genomes may help researchers develop more representative disease-risk models, identify previously unrecognized therapeutic targets, and evaluate whether genetic variants affect treatment outcomes differently among patient populations.

Implications for Pharmacogenomics and Medication Management

One of the most significant potential applications of the expanded dataset is pharmacogenomics, which examines how genetic variation affects medication response. Larger and more diverse datasets may improve understanding of variants associated with altered drug metabolism, reduced treatment efficacy, or increased toxicity.

The resource could support research involving gene–drug relationships, medication-associated adverse events, treatment adherence, prescribing patterns, and health disparities. Investigators may also be able to examine how genetic factors interact with comorbidities, concurrent therapies, environmental exposures, and social determinants of health.

All of Us has already been identified as an important resource for expanding pharmacogenomic research beyond populations that have traditionally dominated genetic studies. More representative evidence may eventually improve the accuracy of clinical decision-support tools and help prevent the inappropriate extrapolation of genetic findings across populations.

However, the expanded dataset does not immediately change medication-selection recommendations. Findings generated through the program will still require validation, prospective evaluation, and translation into evidence-based clinical guidance before they can be routinely incorporated into pharmacy practice.

Funding Uncertainty Clouds Future Prospects

The data release comes as the program faces uncertainty regarding long-term federal support. All of Us has been funded through annual appropriations and funding authorized under the 21st Century Cures Act. NIH reported that program funding fell to about $158 million in fiscal year 2025, representing an approximate 71% reduction from fiscal year 2023 levels. The agency stated that the reductions have affected enrollment, data collection, and development of a pediatric cohort.

Continued support will be important to maintain participant engagement, protect stored data and biospecimens, and expand the longitudinal information necessary to translate large-scale genomic findings into clinically meaningful tools. For the research and pharmacy communities, the program represents a potentially important foundation for more individualized medication use—but its long-term impact will depend not only on the size of the database, but on the quality of its evidence, the diversity of its participants, and the successful translation of research findings into accessible and equitable patient care.